Table 1.
Clinical characteristics of the studied population.
| Variable | Cohort (N = 277) |
|---|---|
| Age at surgery, mean (95% CI) | 45.1 (43.4 - 46.8) |
| Female, No (%) | 117 (42.2) |
| KPS1 at admission, median (Q1, Q3) | 90 (80, 90) |
| Time from radiological diagnosis to surgery in months, median (Q1, Q3) | 1 (1-3) |
| WHO2 grade 2, No (%) | 182 (65.7) |
| WHO grade 3, No (%) | 95 (34.3) |
| WHO 20163, No (%) | |
| Oligodendroglioma | 73 (26.3) |
| IDH-mutated astrocytoma | 67 (24.2) |
| IDH wild-type astrocytoma | 82 (29.6) |
| Not characterized molecularly | 55 (19.9) |
| Asymptomatic, No (%) | 19 (6.9) |
| Epilepsy, No (%) | 181 (65.3) |
| Any focal neurological deficit at admission, No (%) | 79 (28.5) |
| Choice of neurosurgical intervention, No (%) | |
| Biopsy only | 55 (19.9) |
| Main tumor location, No (%) | |
| Frontal | 148 (53.4) |
| Insular | 21 (7.6) |
| Occipital | 1 (0.4) |
| Parietal | 30 (10.8) |
| Temporal | 65 (23.5) |
| Central, deep, basal ganglia, or thalamus | 12 (4.3) |
| Presumed eloquence, No (%) | 182 (65.7) |
| Largest diameter in millimeters, mean (95% CI) | 52.0 (49.6 - 54.4) |
| Tumor volume4 in ml, median (Q1, Q3) | 47.4 (21.5 - 86.4) |
| Tumor volume5 in ml, median (Q1, Q3) | 56.9 (27.1 - 105.6) |
1 Karnofsky performance status. 2 World Health Organization. 3 2016 WHO Classification of the Tumors of the Central Nervous System. 4 Tumor volumes computed in patient space. 5 Tumor volumes computed after registration to MNI space. For convenience, all volumes are reported in milliliters.